XOMA-213

Synonyms: LFA-102; X213
XOMA-213 (LFA-102; X213) 是一种靶向催乳素受体 (PRLR) 的人类单克隆抗体 (mAb),针对人源靶点的 Kd 值为 2 nM,可阻断 PRL 诱导的细胞增殖,抑制包括 PRL 和人生长激素 (hGH) 在内的多种 PRLR 配体的激活作用,抑制细胞中 PRL 诱导的 Stat5、Akt 和 ERK1/2 磷酸化,并可诱导肿瘤消退、延缓疾病进展、抑制 PRLR 信号传导与肿瘤生长,因此可用于乳腺癌的相关研究。
XOMA-213
产品编号: MS-O22836 纯度: 98.46% 分子量: 147.29 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

XOMA-213 (LFA-102; X213) 是一种靶向催乳素受体 (PRLR) 的人类单克隆抗体 (mAb),针对人源靶点的 Kd 值为 2 nM,可阻断 PRL 诱导的细胞增殖,抑制包括 PRL 和人生长激素 (hGH) 在内的多种 PRLR 配体的激活作用,抑制细胞中 PRL 诱导的 Stat5、Akt 和 ERK1/2 磷酸化,并可诱导肿瘤消退、延缓疾病进展、抑制 PRLR 信号传导与肿瘤生长,因此可用于乳腺癌的相关研究。

生物实验数据

生物活性 XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting the prolactin receptor (PRLR) with a Kd of 2 nM for the human target, which blocks PRL-induced cell proliferation, inhibits the activation by multiple PRLR ligands including PRL and human growth hormone (hGH), suppresses PRL-induced phosphorylation of Stat5, Akt, and ERK1/2 in cells, and induces tumor regression, delays disease progression, and inhibits PRLR signaling and tumor growth, making it suitable for research related to breast cancer.
IC50 & Target

STAT5

 

体外研究
(In Vitro)

XOMA-213 (10 μg/mL) 可特异性结合 T47D、MCF7、Nb2-11、BaF3/hPRLR 细胞及原代人乳腺肿瘤细胞表面表达的天然人源和大鼠源 PRLR,但不结合小鼠 PRLR 或 PRLR 阴性的 BaF3 细胞。
XOMA-213 (0.01-10 μg/mL; 45 min pre-incubation on ice) 可结合 T47D 细胞,且不会干扰 PRL-PRLR 相互作用,呈现非配体竞争性结合模式。
XOMA-213 (0.05-10 μg/mL; 30 min pre-incubation at 37°C) 可强效抑制 T47D 细胞中 hPRL 诱导的 Stat5、Akt 和 ERK1/2 磷酸化,抑制 MCF7 细胞中 hPRL 诱导的 Stat5 磷酸化,并完全阻断 ER+/PR+/HER2- 原代人乳腺肿瘤细胞中 hPRL 诱导的 Stat5 磷酸化,且无可检测到的激动活性。
XOMA-213 (0.01-100 μg/mL; 96-168 h) 可完全阻断 hPRL 诱导的 T47D 细胞增殖,高效抑制 Nb2-11 细胞存活,抑制 BaF3/hPRLR 细胞中 hPRL 和 hGH 诱导的增殖 (EC50 = 0.5 μg/mL),并抑制 BaF3/hPRLR/hPRL 细胞中自分泌 PRL 依赖性生长,在高配体环境中的表现优于配体竞争性拮抗剂。
XOMA-213 (0.001-100 μg/mL; 24 h) 可诱导针对 T47D 细胞的抗体依赖的细胞介导的细胞毒性 (ADCC),最大细胞杀伤率达 50%,EC50 为 0.13 μg/mL,显示出一种额外的抗肿瘤作用机制。

Western Blot Analysis

Cell Line: T47D human ER+ breast cancer cells, MCF7 human ER+ breast cancer cells, dissociated primary human breast tumor cells (ER+/PR+/HER2-)
Concentration: 0.05, 0.1, 0.5, 1, 5 μg/mL (T47D/MCF7 cells); 10 μg/mL (primary tumor cells); 50 ng/mL hPRL
Incubation Time: 30 min (pre-incubation at 37°C); 30 min (hPRL stimulation)
Result: Neutralized hPRL-induced phosphorylation of Stat5, Akt, and ERK1/2 in a concentration-dependent manner in T47D cells.
Antagonized hPRL-induced Stat5 phosphorylation efficiently in MCF7 cells.
Completely neutralized hPRL-induced Stat5 phosphorylation in primary human breast tumor cells at 10 μg/mL.
Did not induce PRLR signaling in any cell type alone.

Cell Proliferation Assay

Cell Line: T47D human ER+ breast cancer cells, Nb2-11 rat pre-T cell lymphoma cells, BaF3/hPRLR cells, BaF3/hPRLR/hPRL cells
Concentration: 10 μg/mL (T47D cells); 0.01-10 μg/mL (Nb2-11 cells); 0.01-10 μg/mL, 10 μg/mL (BaF3/hPRLR cells with hPRL); 0.03-3 μg/mL (BaF3/hPRLR cells with hGH); 0.01-100 μg/mL (BaF3/hPRLR/hPRL cells); 10-2000 ng/mL hPRL; 50 ng/mL hPRL; 1-100 ng/mL hPRL; 50 ng/mL hGH
Incubation Time: 96 h (T47D cells); 96 h (BaF3/hPRLR cells with hPRL); 168 h (BaF3/hPRLR/hPRL cells)
Result: Completely neutralized hPRL-induced proliferation of T47D cells at physiological and super-physiological hPRL concentrations.
Completely inhibited Nb2-11 cell survival.
Inhibited hPRL-dependent growth of BaF3/hPRLR cells with an EC50 of 0.5 μg/mL, efficiently neutralized signaling even at high hPRL concentrations, and potently blocked hGH-induced proliferation.
Suppressed baseline autocrine Stat5 signaling and inhibited growth of BaF3/hPRLR/hPRL cells, while other PRLR antagonists did not.
体内研究
(In Vivo)

XOMA-213 (10 mg/kg;静脉注射;单次给药) 可完全阻断雌性 SCID 小鼠体内 T47D-T2 人乳腺癌异种移植物中的催乳素受体信号通路。
XOMA-213 (0.01-10 mg/kg;腹腔注射;单次给药) 可诱导 Nb2-11-luc 淋巴瘤异种移植瘤消退,并显著延长雌性 SCID 小鼠的疾病进展时间。
XOMA-213 (300 mg/kg;腹腔注射) 可抑制 DMBA 诱导的大鼠乳腺肿瘤生长并使其消退。
XOMA-213 (腹腔注射;每日 1 次,连续 5 天,剂量 50 mg/kg) 可显著提高去卵巢雌性大鼠的血清 PRL 水平,表明其可有效中和全身的催乳素受体。

Animal Model: SCID mice (female)
Dosage: 10 mg/kg
Administration: i.v.; single dose
Result: Completely blocked ovine PRL-induced intra-tumoral phosphorylated Stat5 (p-Stat5) levels, with no detectable p-Stat5 observed in treated tumors.
Reached serum levels ranging from 30-56 μg/mL at sample collection.
Animal Model: SCID mice (female)
Dosage: 0.01-10 mg/kg
Administration: i.p.; single dose
Result: Induced disease regression by day 3 post-dosing at ≥0.3 mg/kg, with efficacy sustained through day 14 post-dosing relative to controls.
Reduced mean photon count to 5.6 × 105 photons/second in the 10 mg/kg group on day 14, compared to 1.7 × 109 photons/second for controls.
Significantly prolonged time to progression for groups receiving ≥0.3 mg/kg relative to controls.
Animal Model: rats (female; DMBA-induced mammary tumor model)
Dosage: 300 mg/kg (monotherapy); 300 mg/kg (combination therapy)
Administration: i.p.; twice weekly (monotherapy); three times weekly (combination therapy)
Result: Exhibited significant anti-tumor activity from study days 10 through 27 post-dosing as monotherapy, with 33% of tumors regressing compared to 11% spontaneous regression in controls.
Showed significant efficacy relative to vehicle from days 9-20 post-dosing as monotherapy or combined with letrozole; combination had higher activity than letrozole alone from days 6-16 post-dosing.
Achieved 20% tumor regression with monotherapy and 47% with combination on day 20, compared to 0% with letrozole alone or vehicle.
Resulted in mean tumor volume of 809 mm3 with monotherapy and 436 mm3 with combination on day 20, compared to 1964 mm3 for vehicle.
Animal Model: rats (ovariectomized female)
Dosage: 50 mg/kg
Administration: i.p.; daily; 5 days
Result: Significantly elevated mean serum rat PRL levels on days 1-7 relative to controls, with a positive correlation between serum LFA102 levels and elevated PRL.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT01338831Novartis Pharmaceuticals
Castration-resistant Prostate Cancer|Metastatic Breast Cancer|Uterine Leiomyoma
2011-09PHASE1
NCT01610050Novartis Pharmaceuticals
Castration-resistant Prostate Cancer, Advanced Breast Cancer
2012-06PHASE1
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 147.29 kDa
别名 LFA-102; X213

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础